These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 19996401)
1. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. Tsai TT; Maddox TM; Roe MT; Dai D; Alexander KP; Ho PM; Messenger JC; Nallamothu BK; Peterson ED; Rumsfeld JS; JAMA; 2009 Dec; 302(22):2458-64. PubMed ID: 19996401 [TBL] [Abstract][Full Text] [Related]
2. Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Barnes GD; Stanislawski MA; Liu W; Barón AE; Armstrong EJ; Ho PM; Klein A; Maddox TM; Nallamothu BK; Rumsfeld JS; Tsai TT; Bradley SM Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):406-13. PubMed ID: 27245070 [TBL] [Abstract][Full Text] [Related]
10. The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. Kenaan M; Seth M; Aronow HD; Wohns D; Share D; Gurm HS; J Am Coll Cardiol; 2013 Dec; 62(22):2083-9. PubMed ID: 24055844 [TBL] [Abstract][Full Text] [Related]
11. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. Chhatriwalla AK; Amin AP; Kennedy KF; House JA; Cohen DJ; Rao SV; Messenger JC; Marso SP; JAMA; 2013 Mar; 309(10):1022-9. PubMed ID: 23483177 [TBL] [Abstract][Full Text] [Related]
12. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. ADVANCE MI Investigators Am Heart J; 2005 Jul; 150(1):116-22. PubMed ID: 16084157 [TBL] [Abstract][Full Text] [Related]
13. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
14. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). Marui A; Kimura T; Nishiwaki N; Mitsudo K; Komiya T; Hanyu M; Shiomi H; Tanaka S; Sakata R; Am J Cardiol; 2014 Aug; 114(4):555-61. PubMed ID: 24996550 [TBL] [Abstract][Full Text] [Related]
15. Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. Waksman R; Wolfram RM; Torguson RL; Okubagzi P; Xue Z; Suddath WO; Satler LF; Kent KM J Invasive Cardiol; 2006 Aug; 18(8):370-5. PubMed ID: 16877786 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342 [TBL] [Abstract][Full Text] [Related]
17. Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention. Delhaye C; Maluenda G; Wakabayashi K; Ben-Dor I; Collins SD; Syed AI; Gonzalez MA; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R Am J Cardiol; 2010 Feb; 105(3):297-301. PubMed ID: 20102938 [TBL] [Abstract][Full Text] [Related]
18. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632 [TBL] [Abstract][Full Text] [Related]
19. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G; Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196 [TBL] [Abstract][Full Text] [Related]
20. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Coons JC; Seybert AL; Saul MI; Kirisci L; Kane-Gill SL Ann Pharmacother; 2005 Oct; 39(10):1621-6. PubMed ID: 16105872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]